Albemarle Corp. vs Amylx Pharmaceuticals Inc — how do they compare? Albemarle Corp. trades at $131.54 (market cap $15.27B), while Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B). The key difference: Albemarle Corp. is far larger — about 5.8× Amylx Pharmaceuticals Inc's market cap, and Albemarle Corp. pays a 1.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALB | AMLX | |
|---|---|---|
Market Cap | $15.27B | $2.64B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $24.19 |
52-Week Low | $72.58 | $7.82 |
Enterprise Value | $17.75B | $2.39B |
Dividend Yield | 1.27% | — |
Trailing returns across standard periods
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →